Legacy Healthcare to Advance Topical Solution Cinainu into International Phase 3 Trial for Alopecia Areata following US FDA Clearance

RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to severe alopecia areata (AA) in at least 500 subjects. Cinainu is the first topical drug-candidate for both patients with severe and moderate AA, allowing early-treatment before...